Related Experiment Video

Updated: Aug 9, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Selected topics of hypoglycemia care

Bernd Koch

    Canadian Family Physician Medecin De Famille Canadien
    |April 28, 2006
    PubMed

    Insights

    Hypoglycemia (HoG) diagnosis relies on clinical signs or glucometer readings. While intensified diabetes treatment may increase HoG incidence, chronic risks are rare, and prevention is possible through education and vigilance.

    Area of Science:

    • Endocrinology
    • Metabolic Disorders
    • Diabetes Management

    Background:

    • Hypoglycemia (HoG) is a common concern in diabetes management.
    • Understanding HoG diagnosis, risk factors, and prevention is crucial for patient safety.

    Purpose of the Study:

    • To review key aspects of hypoglycemia care including diagnosis, predisposing factors, adverse effects, and prevention strategies.
    • To synthesize evidence from various sources to inform clinical practice.

    Main Methods:

    • Literature search of MEDLINE using keywords 'hypoglycemia' and 'diabetes mellitus'.
    • Inclusion of hand-searched relevant sources.
    • Evidence quality primarily level III and IV, based on consensus, observation, and clinical experience.

    Main Results:

    • Hypoglycemia can be diagnosed clinically or with a glucometer; post-mortem diagnosis is not possible.
    • Blood glucose testing for HoG is recommended only for patients on insulin or insulin secretagogues.
    • Increased incidence of HoG is expected with intensified diabetes treatment, but chronic morbidity and mortality are considered rare.

    Conclusions:

    • Clinical diagnosis of HoG should be emphasized; blood glucose testing is vital when patients are unaware of symptoms.
    • Patients not using insulin or secretagogues do not need to fear or test for HoG.
    • Vigilance for HoG is essential in specific populations, including those with cardiac arrhythmias, drivers, and individuals in high-risk occupations.
    Abstract

    Related Concept Videos

    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    Hypoglycemia01:26

    Hypoglycemia

    Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
    Hyperglycemia01:29

    Hyperglycemia

    Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    SBAR II: Application of SBAR01:14

    SBAR II: Application of SBAR

    SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
    SBAR Report from a Nurse to a Health Care Provider
    S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...